Cite
MLA Citation
Lei Zheng et al.. “812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer.” Journal for immunotherapy of cancer, vol. 8, n.d., p. A862. http://access.bl.uk/ark:/81055/vdc_100144729888.0x000004